Key terms

About IRWD

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IRWD news

Yesterday 2:37pm ET Ironwood Pharmaceuticals: A Strong Buy on Promising Gastrointestinal Treatment Prospects and Market Expansion Opportunities Yesterday 1:30pm ET Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD) Yesterday 7:39am ET Ironwood announces results from STARGAZE trial Mar 22 11:07am ET Jefferies retail/healthcare analysts to hold an analyst/industry conference call Mar 16 12:36pm ET Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge Mar 01 12:55pm ET Ironwood put volume heavy and directionally bearish Mar 01 9:02am ET Ironwood price target lowered to $18 from $21 at Craig-Hallum Mar 01 8:37am ET Ironwood Pharma: A Strong Buy on Apraglutide’s Success and Undervalued Market Potential Mar 01 7:42am ET Ironwood price target lowered to $14 from $20 at Wells Fargo Feb 29 3:16pm ET Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential Feb 29 11:01am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD) Feb 29 9:30am ET Analysts’ Top Healthcare Picks: Trulieve Cannabis (TCNNF), Avid Bioservices (CDMO) Feb 29 6:24am ET Ironwood reports ‘positive’ results from Phase III trial of apraglutide Feb 26 12:30am ET Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC), AMN Healthcare Services (AMN) and Ironwood Pharma (IRWD) Feb 22 10:14am ET Jefferies biotechnology analysts hold an analyst/industry conference call Feb 16 8:34am ET Ironwood price target raised to $21 from $20 at Piper Sandler Feb 15 3:10pm ET Ironwood price target raised to $18 from $15 at Capital One Feb 15 2:45pm ET Ironwood Pharma: A Strong Buy on Solid Financials and a Promising Pipeline Feb 15 2:06pm ET Ironwood Pharmaceuticals Receives ‘Buy’ Rating from Analyst Amid Strong Performance and Promising Drug Pipeline Feb 15 7:11am ET Ironwood sees FY24 revenue $435M-$455M, consensus $462.82M Feb 15 7:09am ET Ironwood reports Q4 EPS 0c, consensus 21c Feb 13 7:41am ET Analysts Are Bullish on These Healthcare Stocks: Ironwood Pharma (IRWD), Gilead Sciences (GILD) Feb 12 8:29am ET Ironwood Pharma (IRWD) Gets a Buy from Craig-Hallum Feb 12 4:55am ET Piper Sandler healthcare analysts to hold an analyst/industry conference call Feb 05 5:12pm ET Piper Sandler healthcare analysts to hold an analyst/industry conference call Jan 17 9:01am ET Craig-Hallum bullish on Ironwood, initiates with a Buy Jan 17 7:23am ET Ironwood initiated with a Buy at Craig-Hallum Jan 12 7:26am ET Ironwood price target raised to $10.50 from $9 at TD Cowen Jan 12 6:20am ET Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK) Jan 08 8:05pm ET Ironwood Pharma: A Strong Buy on Robust Sales Growth and Promising Pipeline Jan 08 7:00pm ET Ironwood announces publication of Phase III study in The Lancet

No recent news articles are available for IRWD

IRWD Financials

1-year income & revenue

Key terms

IRWD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IRWD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms